Maropitant (Cerenia) for Vomiting in Dogs and Cats: Clinical Evidence

Bottom line

• Maropitant is a selective NK1 (neurokinin-1) receptor antagonist that blocks substance P at both the central emetic center and peripheral emetic reflex arcs, giving it broad antiemetic activity across motion, chemical, vestibular, and uremic emetic triggers [1][3].
• For canine motion sickness, a randomized, placebo-controlled program reduced vomiting incidence by 86.1% (dosed ~2 h before travel) and 76.5% (~10 h before travel); in the pivotal analysis 15/106 maropitant-treated dogs vomited vs 69/105 on placebo (P < 0.0001) [1].
• For feline CKD-associated vomiting, a blinded, placebo-controlled trial (41 enrolled, 33 completed) showed a significant drop in vomiting (median 0 vs 2 episodes over 14 days; P < 0.01) but NO significant change in appetite, body weight, or serum creatinine at 2 weeks — palliation of vomiting, not disease modification [2].
• As of July 2026, head-to-head data narrow maropitant's edge in specific niches: for dexmedetomidine-induced vomiting in cats it is effective but no better than ondansetron or metoclopramide (P < 0.001 vs saline; no difference among the three) [4]; for canine ovariohysterectomy, two small RCTs support a visceral-analgesia adjunct role beyond its label [5][6].
• FDA-approved in dogs only (tablets and injectable) for prevention of acute vomiting and motion-sickness vomiting; feline use is off-label but well established and trial-supported [3].

Drug facts

• Class: Neurokinin-1 (NK1) receptor antagonist (antiemetic) [3]
• Mechanism: Selectively antagonizes NK1 receptors, blocking the pharmacological action of substance P in the CNS emetic center and at peripheral emetic reflex arcs; suppresses both central/vestibular and peripheral emetic stimuli [1][3]. Because substance P/NK1 signaling also participates in nociceptive transmission, the same receptor blockade underlies the emerging visceral-analgesia signal (see multimodal section) [5][6].
• Route: Oral tablets (dogs, FDA-labeled); injectable solution (FDA-labeled in dogs); used off-label orally and by injection in cats [3].
• Indication: FDA-approved for prevention of acute vomiting and motion-sickness vomiting in dogs ≥2 months of age; off-label antiemetic use in cats is well established and supported by controlled trials [1][2][3].
• Approval: FDA-approved (NADA 141-263), Zoetis; CERENIA initially approved 2007 [3].
• Formulations (per label): Peach, oval, scored tablets in 16, 24, 60, and 160 mg; consult the current label for weight-based dosing [3].
• Label contraindications/cautions: Dogs younger than 7 weeks; not for use in breeding, pregnant, or lactating animals; use with caution in hepatic dysfunction (hepatically metabolized) [3].
• Label common AEs: Pain or vocalization at the SC injection site; hypersalivation at high oral doses; sedation at supratherapeutic doses [3].

What the evidence shows

Efficacy: canine motion sickness (labeled indication)

Conder et al. (2008) reported two randomized, placebo-controlled trials across 26 veterinary clinics, with 163 of 189 dogs evaluable for efficacy. Maropitant was given orally approximately 2 h (Trial 1) or 10 h (Trial 2) before a 60-minute automobile ride, with vomiting incidence during the ride as the primary outcome. Maropitant reduced vomiting by 86.1% and 76.5% at the 2 h and 10 h pre-travel time points, respectively; in the pivotal analysis 15/106 maropitant-treated dogs vomited compared with 69/105 placebo-treated dogs (P < 0.0001). An earlier exploratory arm of 17 dogs showed 3/17 (maropitant) vs 10/17 (placebo) vomiting. Recovery-phase behaviors (aimless movement, vocalization, panting) were also reduced in treated dogs [1]. This is the anchor evidence for the labeled canine antiemetic/anti-motion-sickness claim.

Efficacy and safety: feline CKD-associated vomiting

Quimby et al. (2015) enrolled 41 cats with stable IRIS Stage II–III CKD and chronic uremic vomiting in a blinded, randomized, placebo-controlled trial; 33 completed (21 maropitant, 12 placebo). Oral maropitant once daily for 2 weeks produced a statistically significant reduction in vomiting frequency (median 0 episodes on maropitant vs 2 on placebo over 14 days; P < 0.01). Critically, appetite scores, activity scores, body weight, and serum creatinine did NOT differ significantly between groups over the 2-week period. The authors concluded maropitant palliates uremic vomiting but does not, in the short term, broadly improve appetite, weight, or renal parameters [2].

A separate dispatch had described a "2024 prospective study" reporting that maropitant reduced vomiting in CKD cats while creatinine, BUN, and phosphorus remained statistically unchanged versus controls — reassuring that antiemetic therapy did not mask worsening azotemia. On verification, that dispatch resolves to the same Quimby et al. dataset (PMC11104052), not an independent study; it is therefore represented here once [2]. The practical read-through is unchanged and clinically useful: routine monitoring of creatinine, BUN, and phosphorus remains informative in a CKD cat on maropitant — the antiemetic controls the symptom without distorting the renal panel.

Comparators: is maropitant superior to other antiemetics?

For the narrow, common scenario of alpha-2 agonist (dexmedetomidine)-induced vomiting in cats, the answer as of July 2026 is no. Gölgeli Bedir et al. (2025) randomized 64 cats to saline, maropitant (SC), ondansetron (IM), or metoclopramide (IM) 30 minutes before dexmedetomidine. All three antiemetics significantly reduced retching, vomiting duration, and vomiting severity versus saline (P < 0.001), with no significant difference among the three agents. No group — including controls — differed in sialorrhea (P = 0.34) or lip licking (P = 0.12) [4].

This is a genuinely contested point worth presenting squarely:

• The mechanistic prior favored maropitant: dexmedetomidine triggers emesis via alpha-2 adrenoceptors in the area postrema/nucleus tractus solitarius, and maropitant's central NK1 blockade sits at the emetic center [3][4]. One might predict an NK1 antagonist would outperform a 5-HT3 antagonist (ondansetron) or a D2 antagonist/prokinetic (metoclopramide).
• The trial data contradict that prior: all three block the emetic response equally well downstream of alpha-2 stimulation, so no mechanism-based advantage was demonstrable for this indication [4].
• Neutral synthesis: for preventing dexmedetomidine-induced emesis in cats, agent choice can reasonably be driven by availability, cost, and route rather than efficacy. Maropitant remains a fully valid choice — it simply is not a differentiated one here. This does not generalize to other emetic etiologies (motion, uremic, chemotherapy), where maropitant's broad central+peripheral profile and comparator data differ [1][2].

Multimodal / off-label: visceral analgesia in canine ovariohysterectomy

Two randomized trials extend maropitant beyond antiemesis into perioperative visceral analgesia — an off-label, adjunct role, not a standalone analgesic claim:

• Bozkurt et al. (2024) randomized 36 bitches to maropitant, meloxicam, or control for ovariohysterectomy. No animal required rescue analgesia, but pain scores in the maropitant group were significantly lower than the other groups (P < 0.05), and the authors concluded maropitant provided more effective visceral analgesia than meloxicam. C-reactive protein (an anti-inflammatory/systemic-inflammation marker) did not differ between groups — the analgesic effect was not mirrored by a measurable anti-inflammatory difference [5].
• Ramírez-Castillo et al. (2026) randomized 30 female dogs to a maropitant citrate CRI (100 mcg/kg/h) or a lidocaine CRI, using parasympathetic-tone (PTA/nociception) monitoring intraoperatively. Only the maropitant group showed a significant fall in the parasympathetic-tone energy variable, and the authors concluded maropitant reduced the nociception-related sympathetic response comparably to lidocaine [6].

Synthesis: these are small, single-procedure soft-tissue-surgery trials. They add controlled, prospective support for a perioperative analgesic adjunct role grounded in NK1/substance-P nociceptive signaling, and they are mechanistically consistent with each other (lower pain scores in one; blunted intraoperative nociception in the other). They do not establish maropitant as a standalone analgesic and do not change any approved dosing, which remains a label/formulary decision. Note the boundary: equal antiemetic performance in the dexmedetomidine study [4] and a visceral-analgesia signal in OVH [5][6] are separate questions — one is about blocking emesis, the other about blunting nociception — and the OVH analgesia data are not undercut by the dexmedetomidine emesis result.

Contraindications, precautions & PK

• Contraindications/cautions (label): Not for dogs younger than 7 weeks; not for use in breeding, pregnant, or lactating animals; use with caution or avoid in hepatic dysfunction because maropitant undergoes hepatic metabolism [3].
• Adverse effects (label): SC injection-site pain/vocalization; hypersalivation at high oral doses; sedation at supratherapeutic doses. In the feline dexmedetomidine RCT, no antiemetic altered sialorrhea or lip licking [3][4].
• Renal population PK/safety: In CKD cats, maropitant did not produce statistically significant changes in creatinine, BUN, or phosphorus over 2 weeks versus placebo — supporting short-term renal safety and confirming the renal panel stays interpretable during therapy [2].
• Species labeling: Oral tablets and injectable are FDA-labeled in dogs only; feline use (oral or injectable) is off-label but trial-supported [1][2][3].
• Duration of evidence: Controlled feline CKD data extend to 2 weeks; longer-term feline use is common but rests on clinician judgment rather than controlled long-term data [2].

Practical decision support

• Canine motion sickness: First-line, on-label. Dose ~2 h before travel for maximal effect (86.1% reduction) or up to ~10 h prior if earlier dosing is more practical (76.5% reduction) [1].
• Feline CKD vomiting: Reasonable, trial-supported palliation of uremic emesis. Counsel owners that vomiting should improve but appetite and weight gains are not reliably seen short-term; pair with dedicated appetite stimulants (e.g., capromorelin, mirtazapine) if inappetence is the dominant problem [2]. Keep monitoring the renal panel — maropitant does not mask azotemia [2].
• Perioperative emesis prophylaxis in cats (dexmedetomidine protocols): Maropitant, ondansetron, and metoclopramide are interchangeable on efficacy; choose on availability, cost, and route (maropitant SC, the others IM in the trial) [4].
• Perioperative visceral pain (canine soft-tissue/OVH): Consider maropitant as a multimodal adjunct, not a standalone analgesic; current data are small-trial and off-label, and do not alter approved dosing [5][6].
• Hepatic dysfunction: Use with caution given hepatic metabolism [3].

Frequently Asked Questions

Is maropitant FDA-approved for use in cats? No. Maropitant tablets and injectable are FDA-labeled in dogs only. Feline use — oral or injectable — is off-label but widely practiced and supported by controlled trials in CKD vomiting and perioperative emesis [2][3][4].

How does maropitant work? It is a selective NK1 receptor antagonist that blocks substance P at both the central emetic center (medulla) and peripheral emetic reflex arcs, suppressing a broad range of vomiting stimuli. The same NK1/substance-P pathway participates in nociception, which underlies its emerging visceral-analgesia signal [1][3][6].

Can maropitant prevent motion-sickness vomiting in dogs? Yes — this is a labeled indication. In the Conder et al. 2008 randomized trials, maropitant cut vomiting by 86.1% when given ~2 h before travel and 76.5% when given ~10 h before (15/106 vs 69/105 placebo in the pivotal analysis; P < 0.0001) [1].

Does maropitant improve appetite or weight in cats with CKD? Not reliably in the short term. Quimby et al. 2015 showed a significant reduction in vomiting (median 0 vs 2 episodes over 14 days; P < 0.01) but no significant change in appetite, body weight, or serum creatinine at 2 weeks. It palliates vomiting rather than modifying disease [2].

Should I keep monitoring kidney values in a CKD cat on maropitant? Yes. In the Quimby dataset, creatinine, BUN, and phosphorus were statistically unchanged versus placebo, so the antiemetic controls the symptom without masking azotemia — the renal panel remains fully informative and routine monitoring is still recommended [2].

Is maropitant better than ondansetron or metoclopramide for dexmedetomidine-induced vomiting in cats? No. In the Gölgeli Bedir et al. 2025 RCT (64 cats), all three significantly outperformed saline (P < 0.001) with no significant difference among them. Choose based on availability, cost, and route rather than efficacy for this specific indication [4].

Does maropitant provide analgesia in addition to its antiemetic effect? Emerging evidence in dogs suggests yes, as a perioperative adjunct. Two randomized OVH trials found maropitant lowered postoperative pain scores versus meloxicam (Bozkurt 2024) and blunted intraoperative nociception comparably to lidocaine (Ramírez-Castillo 2026). It is not established as a standalone analgesic, and these findings do not change approved dosing [5][6].

Is maropitant safe for dogs with liver disease? Use with caution. Maropitant is hepatically metabolized, and the label advises caution or avoidance in animals with hepatic dysfunction; consult the current prescribing information and formulary [3].

Changelog

• 2026-06-06: First published (Conder 2008 canine motion sickness; Quimby 2015 feline CKD; DailyMed CERENIA label).
• 2026-07-06: Consolidated three dated dispatches into this evergreen hub. Added Gölgeli Bedir 2025 (dexmedetomidine comparator RCT, cats) and the Bozkurt 2024 + Ramírez-Castillo 2026 visceral-analgesia OVH trials. Merged the "2026-06-15 CKD" dispatch into the Quimby entry after verifying it cited the same PMC11104052 dataset (no new study); no duplicate citation created. Reorganized evidence by clinical question (efficacy, comparators, safety, special populations, multimodal) and added contested-evidence synthesis for the dexmedetomidine comparison.